Defining "value" in cancer care goes beyond survival and should encompass patient quality of life metrics, said Coral Omene, MD, PhD, of Robert Wood Johnson Medical School.

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...